Actively Recruiting
Efficacy of NBI-1117568 in Preventing Relapse in Adults With Schizophrenia
Led by Neurocrine Biosciences · Updated on 2026-04-15
560
Participants Needed
17
Research Sites
184 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The main objective of the study is to evaluate NBI-1117568 compared with placebo in delaying relapse of symptoms of schizophrenia in adults who have a stable response after open-label treatment with NBI-1117568.
CONDITIONS
Official Title
Efficacy of NBI-1117568 in Preventing Relapse in Adults With Schizophrenia
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Participants must have a primary diagnosis of schizophrenia based on DSM-5-TR criteria
- Diagnosis of schizophrenia must have been made at least 1 year before screening
- Participants must have had a positive response to at least one antipsychotic therapy (excluding clozapine) at a therapeutic dose
You will not qualify if you...
- Participants with unstable or poorly controlled medical conditions or chronic diseases within 30 days before Day 1
- Participants with laboratory abnormalities indicating significant unmanaged or undiagnosed disease
- Participants with a history of clozapine treatment for treatment-resistant psychosis
- Participants with psychiatric inpatient stays of 30 or more consecutive days in the 90 days before screening (except for social reasons or other clinical trial participation)
- Participants who started or increased nonpharmacological psychosocial therapy within 3 weeks before screening or expect changes during the study
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 17 locations
1
Neurocrine Clinical Site
Garden Grove, California, United States, 92845
Actively Recruiting
2
Neurocrine Clinical Site
La Habra, California, United States, 90631
Actively Recruiting
3
Neurocrine Clinical Site
Lemon Grove, California, United States, 91945
Actively Recruiting
4
Neurocrine Clinical Site
Oceanside, California, United States, 92056
Actively Recruiting
5
Neurocrine Clinical Site
West Hills, California, United States, 91307
Actively Recruiting
6
Neurocrine Clinical Site
Hollywood, Florida, United States, 33024
Actively Recruiting
7
Neurocrine Clinical Site
Maitland, Florida, United States, 32751
Actively Recruiting
8
Neurocrine Clinical Site
Miami, Florida, United States, 33122
Actively Recruiting
9
Neurocrine Clinical Site
Tampa, Florida, United States, 33629
Actively Recruiting
10
Neurocrine Clinical Site
West Palm Beach, Florida, United States, 33024
Actively Recruiting
11
Neurocrine Clinical Site
Atlanta, Georgia, United States, 30318
Actively Recruiting
12
Neurocrine Clinical Site
Boston, Massachusetts, United States, 02116
Actively Recruiting
13
Neurocrine Clinical Site
Flowood, Mississippi, United States, 39232
Actively Recruiting
14
Neurocrine Clinical Site
Cedarhurst, New York, United States, 11516
Actively Recruiting
15
Neurocrine Clinical Site
New York, New York, United States, 10029
Actively Recruiting
16
Neurocrine Clinical Site
New York, New York, United States, 10036
Actively Recruiting
17
Neurocrine Clinical Site
Bellevue, Washington, United States, 98007
Actively Recruiting
Research Team
N
Neurocrine Medical Information Call Center
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here